Second US approval for Merck, Pfizer’s Bavencio

Merck and Pfizer have announced a second accelerated approval in the US for Bavencio in less than two months, in this instance for certain patients with metastatic urothelial carcinoma.

• Source: pharmatimes
• 581
• May 10, 2017